Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)
Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)
To investigate the safety of Nivolumab in combination with Ipilimumab in subjects with previously untreated advanced or metastatic Renal Cell Cancer.
Inclusion Criteria:
1. Type of Participant and Target Disease Characteristics
Exclusion Criteria:
Medical Conditions
Prior/Concomitant Therapy
Other protocol defined inclusion/exclusion criteria apply
Anchorage, Alaska 99503, United States
Tulsa, Oklahoma 74146, United States